Modality
Degrader
MOA
WRNi
Target
IL-17A
Pathway
Incretin
IgAN
Development Pipeline
Preclinical
~Feb 2021
→ ~May 2022
Phase 1
~Aug 2022
→ ~Nov 2023
Phase 2
Feb 2024
→ Apr 2030
Phase 2Current
NCT06276436
867 pts·IgAN
2024-02→2030-04·Active
867 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-04-074.0y awayPh2 Data· IgAN
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2
Active
Catalysts
Ph2 Data
2030-04-07 · 4.0y away
IgAN
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06276436 | Phase 2 | IgAN | Active | 867 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| Pemitapinarof | BeiGene | Approved | KRASG12C |